Polymorphisms of angiotensin-converting enzyme 2 gene associated with magnitude of left ventricular hypertrophy in male patients with hypertrophic cardiomyopathy

Chinese Medical Journal

Volumn 121, Issue 1, 2008, Pages 27-31

  Wang, Shu Xia ^a   Fu, Chun Yan ^b   Zou, Yu Bao ^b   Wang, Hu ^b   Shi, Yi ^b   Xu, Xi Qi ^b   Chen, Jing Zhou ^b   Song, Xiao Dong ^b   Huan, Tu Jun ^a   Hui, Ru Tai ^a,b  

^a FUWAI HOSPITAL   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Angiotensin converting enzyme 2 gene; Hypertrophic cardiomyopathy; Polymorphism

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE;

ADULT; AGED; ALLELE; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME POLYMORPHISM; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENE SEQUENCE; GENOTYPE; HAPLOTYPE; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE SEPTUM; HEREDITY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PHENOTYPE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; THICKNESS;

EID: 38349159262     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200801010-00006     Document Type: Article

References (25)

1. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997; 336: 775-785.
2. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002; 287: 1308-1320.
3. Seidman JG, Seidman CE. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 2001; 104: 557-567.
4. Houlston RS, Tomilson IP. Modifier genes in humans: strategies for identification. Eur J Hum Genet 1998; 6: 80-88.
5. Schelling P, Fischer H, Ganten D. Angiotensin and cell growth: a link to cardiovascular hypertrophy? J Hypertens 1991; 9: 3-15.
6. Harrap SB, Dominiczak AF, Fraser R, Lever AF, Morton JJ, Foy CJ, et al. Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults. Circulation 1996; 93: 1148-1154.
7. Schunkert H, Hense HW, Holmer SR, Stender M, Perz S, Keil U, et al. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N EngI J.Med 1994; 330: 1634-1638.
8. Iwai N, Ohmichi N, Nakamura Y, Kinoshita M. DD genotype of the angiotensin-converting enzyme gene is a risk factor for left ventricular hypertrophy. Circulation 1994; 90: 2622-2628.
9. Osterop AP, Kofflard MJ, Sandkuijl LA, ten Cate FJ, Krams R, Schalekamp MA, et al. AT1 receptor A/C1166 polymorphism contributes to cardiac hypertrophy in subjects with hypertrophic cardiomyopathy. Hypertension 1998; 32: 825-830.
10. Schmieder RE, Erdmann J, Delles C, Jacobi J, Fleck E, Hilgers K, et al. Effect of the angiotensin II type 2-receptor gene (+1675 G/A) on left ventricular structure in humans. J Am Coll Cardiol 2001; 37: 175-182.
11. Delles C, Erdmann J, Jacobi J, Hilgers KF, Fleck E, Regitz-Zagrosek V, et al. Aldosterone synthase (CYP11B2)-344 C/T polymorphism is associated with left ventricular structure in human arterial hypertension. J Am Coll Cardiol 2001; 37: 878-884.
12. Ishanov A, Okamoto H, Yoneya K, Watanabe M, Nakagawa I, Machida M, et al. Angiotensinogen gene polymorphism in Japanese patients with hypertrophic cardiomyopathy. Am Heart J 1997; 133: 184-189.
13. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87: E1-E9.
14. Danilczyk U, Eriksson U, Crackower MA, Penninger JM. A story of two ACEs. J Mol Med 2003; 81: 227-234.
15. Lieb W, Graf J, Gotz A, Konig IR, Mayer B, Fischer M, et al. Association of angiotensin-converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men. Results of the MONICA Augsburg echocardiographic substudy. J Mol Med 2006; 84: 88-96.
16. Wang P, Zou Y, Fu C, Zhou X, Hui R. MYBPC3 polymorphism is a modifier for expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy. Biochem Biophys Res Commun2005; 329: 796-799.
17. Song L, Zou Y, Wang J, Wang Z, Zhen Y, Hui R, et al. Mutations profile in Chinese patients with hypertrophic cardiomyopathy. Clin Chim Acta 2005; 351: 209-216.
18. Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. J Med Liban 1994; 42: 88-89.
19. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003; 348: 295-303.
20. Tajik AJ, Seward JB, Hagler DJ, Mair DD, Lie JT. Two-dimensional real-time ultrasonic imaging of the heart and great vessels. Mayo Clin Proc 1978; 53: 271-303.
21. Sahn DJ, De Maria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083.
22. Leadon SA, Cerutti PA. A rapid and mild procedure of the isolation of DNA from mammalian cells. Anal Biochem 1982; 120: 282-288.
23. Carrier L, Bonne G, Bahrend E, Yu B, Richard P, Niel F, et al. Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy. Circ Res 1997; 80: 427-434.
24. Fischer M, Baessler A, Schunkert H. Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res 2002; 53: 672-677.
25. Thomas DC, Witte JS. Point: population stratification: a problem for case-control studies of candidate-gene associations? Cancer Epidemiol Biomarkers Prev 2002; 11: 505-512.